Adlai Nortye Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adlai Nortye Ltd (ANL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adlai Nortye Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 6M vs 157,490M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+110.1%) for its tracked peer group.
- Profitability: Its -549.0% net margin compares with 15.8% for the peer group.
- Scale: Adlai Nortye Ltd ranks #139 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Adlai Nortye Ltd accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.05M compares with $1.04M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ANL Sales vs. its Competitors, Q4 2025
With a net margin of -548.95 %, Adlai Nortye Ltd reported lower profitability than its competitors (15.79 %).
Adlai Nortye Ltd generated 0.01 % of the combined sales of its peer group.
API endpoints for this dataset
Adlai Nortye Ltd vs. its Competitors, Q4 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Adlai Nortye Ltd reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adlai Nortye Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adlai Nortye Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adlai Nortye Ltd's competitor groups requires a Commercial License.
Adlai Nortye Ltd's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adlai Nortye Ltd | - | - | - | Yes |
| Competitors combined (156) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ANL Stock Performance relative to its Competitors
ANL Stock Performance relative to High-Confidence Competitors
ANL Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 4 | Erasca Inc | 282.9% | Outperformed |
| 5 | Climb Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adlai Nortye Ltd's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Adlai Nortye Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Adlai Nortye Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Adlai Nortye Ltd |
1,069.55 | 6.47 |
 Astrazeneca Plc |
295,827.18 | 58,739.00 |
 Vertex Pharmaceuticals Inc |
140,582.02 | 12,951.60 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Regeneron Pharmaceuticals Inc |
97,147.78 | 16,896.20 |
 United Therapeutics Corporation |
26,676.67 | 3,154.50 |
| SUBTOTAL | 877,296.08 | 158,795.35 |
Sign in to see all competitors of Adlai Nortye Ltd.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adlai Nortye Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adlai Nortye Ltd's Competitors Named by the Company
Competitive relationships identified from Adlai Nortye Ltd reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Tempest Therapeutics Inc. | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Abbisko Cayman Ltd. | Company report | 85% |
| Betta Pharmaceuticals Co., Ltd. | Company report | 85% |
| Incyte | Company report | 85% |
| Chase Sun Pharmaceutical Co., Ltd. | Company report | 85% |
| Maxinovel Pharmaceuticals Co., Ltd. | Company report | 85% |
| Ascletis Pharma Inc. | Company report | 85% |
| Innate Pharma S.A./AstraZeneca PLC | Company report | 85% |
| Shenzhen Ionova Life Science Co., Ltd. | Company report | 85% |
| Chemocentryx Inc. | Company report | 85% |
| Rottapharm Biotech S.r.l. | Company report | 85% |
| Keythera (Suzhou) Pharmaceutical Co., Ltd. | Company report | 85% |
| Amgen Inc. | Company report | 85% |
| Shanghai Yuyao Biotech Ltd. | Company report | 85% |
Company report basis, confidence, active dates and source counts for Adlai Nortye Ltd's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Adlai Nortye Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Incyte Corporation | Reportable 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Protagonist Therapeutics inc | Single reportable segment 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Adlai Nortye Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adlai Nortye Ltd | 1,070 | 52,618 | -288,846 |
| Astrazeneca Plc | 295,827 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 140,582 | 31,979,259 | 9,817,037 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 97,148 | 1,096,444 | 312,615 |
| United Therapeutics Corporation | 26,677 | 2,253,214 | 936,357 |
| PEERS TOTAL | 876,227 | 1,042,161 | 140,498 |
Adlai Nortye Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| Incyte Corporation | United States 92.15 % |
| Xoma Royalty Corporation | CH 54.36 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adlai Nortye Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 492 companies in Adlai Nortye Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Adlai Nortye Ltd ranks #139 of 492 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 975, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 23.62 % |
| 2 | Johnson and Johnson | 688,377 | 12.89 % |
| 3 | Abbvie Inc | 519,434 | 9.73 % |
| 4 | Merck and Co Inc | 367,314 | 6.88 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 139 | Adlai Nortye Ltd | 1,070 | 0.02 % |
Market cap and industry share for the rest of Adlai Nortye Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Adlai Nortye Ltd's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 134 | Alto Neuroscience Inc | 1,190 | 135.98 % |
| 135 | Maravai Lifesciences Holdings Inc | 1,187 | 169.55 % |
| 136 | Nanobiotix S a | 1,177 | 55.74 % |
| 137 | Gh Research Plc | 1,176 | 38.44 % |
| 138 | Compass Pathways Plc | 1,234 | 12.3% |
| 139 | Adlai Nortye Ltd | 1,070 | 565.16 % |
| 140 | Corvus Pharmaceuticals Inc | 1,234 | 12.3% |
| 141 | Cryoport inc | 1,234 | 12.3% |
| 142 | Harrow Inc | 1,234 | 12.3% |
| 143 | Oric Pharmaceuticals Inc | 1,234 | 12.3% |
| 144 | Jade Biosciences Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Adlai Nortye Ltd's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Adlai Nortye Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.84 % (avg) | -37.8 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.50 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 2.89 % | 7.56 % (avg) | -4.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Adlai Nortye Ltd's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.5x | - |
| P/B | -17.5x | 4.3x | -21.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.84 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adlai Nortye Ltd's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Adlai Nortye Ltd falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Adlai Nortye Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 975 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.89 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Adlai Nortye Ltd's dedicated Suppliers and Customers pages, not here.
Adlai Nortye Ltd's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Adlai Nortye Ltd falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Adlai Nortye Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (57.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Adlai Nortye Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adlai Nortye Ltd | 0.19 | 0.65 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adlai Nortye Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adlai Nortye Ltd | Q4 2025 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| PEERS TOTAL | +11.2 % | +43.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adlai Nortye Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adlai Nortye Ltd | Q4 2025 | - | +10.0 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
Adlai Nortye Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adlai Nortye Ltd | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adlai Nortye Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adlai Nortye Ltd | - | 165.26 |
| Astrazeneca Plc | 28.96 | 5.04 |
| Vertex Pharmaceuticals Inc | 35.52 | 10.85 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Regeneron Pharmaceuticals Inc | 20.35 | 5.75 |
| United Therapeutics Corporation | 20.91 | 8.46 |
| PEERS AVERAGE | 41.05 | 5.52 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.